Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF

NCT04339101 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04339101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04339101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
November 11, 2020
Completion date
October 9, 2025
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, hematologic and lymphocytic disorder, myelodysplastic syndrome, primary myelofibrosis, secondary myelofibrosis